Rima Hajjar

Dr. Rima Hajjar

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2024 in Viruses
Verified
Journal Article
Open access
PDF file
NENila Elumalai
Nila Elumalai
HHHussain Hussain
Hussain Hussain
SNSampath Natarajan
Sampath Natarajan
NSNagarajarao Shamaladevi
Nagarajarao Shamaladevi
RHRima Hajjar
Rima Hajjar
MPMichael John Paidas
Michael John Paidas
The COVID-19 pandemic has been one of the most impactful events in our lifetime, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Multiple SARS-CoV-2 variants were reported globally, and a wide range of symptoms existed. Individuals who contract COVID-19 continue to suffer for a long time, known as long COVID or post-acute sequelae of COVID-19 (PASC). While COVID-19 vaccines were widely deployed, both unvaccinated and vaccinated individuals experienced long-term complications. To date, there are no treatments to eradicate long COVID. We recently conceived a new approach to treat COVID in which a 15-amino-acid synthetic peptide (SPIKENET, SPK) is targeted to the ACE2 receptor binding domain of SARS-CoV-2, which prevents the virus from attaching to the host. We also found that SPK precludes the binding of spike glycoproteins with the receptor carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) of a coronavirus, murine hepatitis virus-1 (MHV-1), and with all SARS-CoV-2 variants. Further, SPK reversed the development of severe inflammation, oxidative stress, tissue edema, and animal death post-MHV-1 infection in mice. SPK also protects against multiple organ damage in acute and long-term post-MHV-1 infection. Our findings collectively suggest a potential therapeutic benefit of SPK for treating COVID-19.

24 May 2024 in Viruses
Verified
Journal Article
Open access
PDF file
HHHussain Hussain
Hussain Hussain
NENila Elumalai
Nila Elumalai
SNSampath Natarajan
Sampath Natarajan
NSNagarajarao Shamaladevi
Nagarajarao Shamaladevi
RHRima Hajjar
Rima Hajjar
MPMichael John Paidas
Michael John Paidas
The COVID-19 pandemic, which emerged in early 2020, has had a profound and lasting impact on global health, resulting in over 7.0 million deaths and persistent challenges. In addition to acute concerns, there is growing attention being given to the long COVID health consequences for survivors of COVID-19 with documented cases of cardiovascular abnormalities, liver disturbances, lung complications, kidney issues, and noticeable cognitive deficits. Recent studies have investigated the physiological changes in various organs following prolonged exposure to murine hepatitis virus-1 (MHV-1), a coronavirus, in mouse models. One significant finding relates to the effects on the gastrointestinal tract, an area previously understudied regarding the long-lasting effects of COVID-19. This research sheds light on important observations in the intestines during both the acute and the prolonged phases following MHV-1 infection, which parallel specific changes seen in humans after exposure to SARS-CoV-2. Our study investigates the histopathological alterations in the small intestine following MHV-1 infection in murine models, revealing significant changes reminiscent of inflammatory bowel disease (IBD), celiac disease. Notable findings include mucosal inflammation, lymphoid hyperplasia, goblet cell hyperplasia, and immune cell infiltration, mirroring pathological features observed in IBD. Additionally, MHV-1 infection induces villous atrophy, altered epithelial integrity, and inflammatory responses akin to celiac disease and IBD. SPIKENET (SPK) treatment effectively mitigates intestinal damage caused by MHV-1 infection, restoring tissue architecture and ameliorating inflammatory responses. Furthermore, investigation into long COVID reveals intricate inflammatory profiles, highlighting the potential of SPK to modulate intestinal responses and restore tissue homeostasis. Understanding these histopathological alterations provides valuable insights into the pathogenesis of COVID-induced gastrointestinal complications and informs the development of targeted therapeutic strategies.

Verified
Journal Article
Open access
PDF file
RRRajalakshmi R
Rajalakshmi R
ACArianna Carden
Arianna Carden
HHHussain Hussain
Hussain Hussain
BDBrian Zachary Druyan Brian Zachary Druyan
Brian Zachary Druyan Brian Zachary Druyan
PCPingping Chen
Pingping Chen
MPMichael John Paidas
Michael John Paidas
Glucagon-like peptide 1 (GLP-1), a hormone derived from the proglucagon gene, regulates various physiological processes; however, its impact on pregnancy outcomes remains poorly understood. Assessing the effects of GLP-1 on neonates is vital as GLP-1 is increasingly administered during pregnancy. This study evaluates the effect of GLP-1 exposure on maternal complications and neonatal defects in mice. Pregnant female A/J mice received subcutaneous injections of recombinant GLP-1 (rGLP-1; 1000 nmol/kg) on embryonic day 1 (EP, early pregnancy) or day 15 (E15, late pregnancy). Maternal and neonatal body weights, morphology, and mortality were recorded, and mRNA sequencing was conducted to analyze gene expression in neonatal tissues. Maternal body weight decreased following rGLP-1 exposure, and pups born to both the early and late exposure groups experienced significant weight loss. Pups in the late exposure group exhibited uniform skin detachment and a dramatically higher mortality rate than those born to the early exposure group. Further, RT-PCR analysis confirms the significantly increased expression of selected genes in the skin and associated pathogenesis. RNA sequencing of pups’ skin, brain, lung, and liver tissues from the late exposure group showed altered gene expression. Since maternal weight loss, increased neonatal mortality, and altered gene expression have been observed, GLP-1 receptor agonists (GLP-1RAs) should be avoided during pregnancy.

1 July 2023 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
RHRima Hajjar
Rima Hajjar
IHInaam Hatoum
Inaam Hatoum
AKAmina Krounbi
Amina Krounbi
RCRabih Chahine
Rabih Chahine
RJRahif Jalloul
Rahif Jalloul
MRMohamad K. Ramadan
Mohamad K. Ramadan

1 June 2021 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
LTLina El Taha
Lina El Taha
TBTony Bazi
Tony Bazi
HMHala Maalouf
Hala Maalouf
RHRima Hajjar
Rima Hajjar
YHYasmin Hasbini
Yasmin Hasbini
DCDina Chamsy
Dina Chamsy